Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Water × Thoracic × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 8 Breast 4 Head & Neck 3 Genitourinary 3 Tumor-Agnostic 2 Other 2 Dermatologic 2 Thoracic 1 Plasma cell 1 Other hematologic neoplasm 1 Lymphoid 1 Endocrine 1

Conditions

Neoplasm Metastasis 1 Lung Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 960 Cisplatin 759 Pemetrexed 705 pembrolizumab 519 Paclitaxel 497 Docetaxel 457 Gemcitabine 353 Radiotherapy 337 Erlotinib Hydrochloride 323 Bevacizumab 282 Nivolumab 277 Etoposide 244 durvalumab 223 Drug Therapy 207 osimertinib 197 atezolizumab 187 Radiosurgery 162 Gefitinib 152 Vinorelbine 131 Magnetic Resonance Spectroscopy 116 Ipilimumab 103 130-nm albumin-bound paclitaxel 103 Cetuximab 95 Topotecan 89 Surgical Procedures, Operative 88 Cyclophosphamide 87 Specimen Handling 85 tislelizumab 82 Irinotecan 81 anlotinib 78

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04863248 2023-04-14

PRESERVE 4

G1 Therapeutics, Inc.

Phase 2 Terminated

10 enrolled 14 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡